[go: up one dir, main page]

EE200400026A - 5-HT retseptori ligandid ja nende kasutamine - Google Patents

5-HT retseptori ligandid ja nende kasutamine

Info

Publication number
EE200400026A
EE200400026A EEP200400026A EEP200400026A EE200400026A EE 200400026 A EE200400026 A EE 200400026A EE P200400026 A EEP200400026 A EE P200400026A EE P200400026 A EEP200400026 A EE P200400026A EE 200400026 A EE200400026 A EE 200400026A
Authority
EE
Estonia
Prior art keywords
receptor ligands
ligands
receptor
Prior art date
Application number
EEP200400026A
Other languages
English (en)
Estonian (et)
Inventor
Phoebe Chiang Yuan-Ching
Andrew Dasilva-Jardine Paul
S. Garigipati Ravi
Guzman-Perez Angel
Albert Novomisle William
Mckowan Welch Willard
Kun-Chin Liu Kevin
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200400026A publication Critical patent/EE200400026A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200400026A 2001-06-21 2002-06-17 5-HT retseptori ligandid ja nende kasutamine EE200400026A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29995301P 2001-06-21 2001-06-21
PCT/IB2002/002293 WO2003000666A1 (en) 2001-06-21 2002-06-17 5-ht receptor ligands and uses thereof

Publications (1)

Publication Number Publication Date
EE200400026A true EE200400026A (et) 2004-06-15

Family

ID=23157027

Family Applications (2)

Application Number Title Priority Date Filing Date
EEP200400026A EE200400026A (et) 2001-06-21 2002-06-17 5-HT retseptori ligandid ja nende kasutamine
EEP200400025A EE200400025A (et) 2001-06-21 2002-06-17 5-HT retseptori ligandid ja nende kasutamine

Family Applications After (1)

Application Number Title Priority Date Filing Date
EEP200400025A EE200400025A (et) 2001-06-21 2002-06-17 5-HT retseptori ligandid ja nende kasutamine

Country Status (39)

Country Link
US (6) US6825198B2 (xx)
EP (2) EP1401820A1 (xx)
JP (2) JP2004534823A (xx)
KR (2) KR100566854B1 (xx)
CN (2) CN1630645A (xx)
AP (1) AP2002002561A0 (xx)
AR (1) AR036095A1 (xx)
AU (1) AU2002309173B2 (xx)
BG (2) BG108491A (xx)
BR (2) BR0210503A (xx)
CA (2) CA2450491A1 (xx)
CR (1) CR7168A (xx)
CZ (2) CZ20033431A3 (xx)
DO (1) DOP2002000412A (xx)
EA (2) EA200301213A1 (xx)
EC (2) ECSP034881A (xx)
EE (2) EE200400026A (xx)
GE (1) GEP20053655B (xx)
GT (1) GT200200120A (xx)
HR (1) HRP20031042A2 (xx)
HU (2) HUP0400251A3 (xx)
IL (2) IL158808A0 (xx)
IS (2) IS7040A (xx)
MA (2) MA27036A1 (xx)
MX (2) MXPA03011941A (xx)
NO (2) NO20035697D0 (xx)
NZ (1) NZ529542A (xx)
OA (2) OA12621A (xx)
PA (1) PA8548901A1 (xx)
PE (1) PE20030268A1 (xx)
PL (2) PL367746A1 (xx)
SK (2) SK15672003A3 (xx)
SV (1) SV2003001102A (xx)
TN (2) TNSN03142A1 (xx)
UA (1) UA74443C2 (xx)
UY (1) UY27343A1 (xx)
WO (2) WO2003000666A1 (xx)
YU (1) YU95303A (xx)
ZA (2) ZA200308843B (xx)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
JP2005504043A (ja) * 2001-08-10 2005-02-10 パラチン テクノロジーズ インク． 生物学的に活性な金属ペプチド類のペプチド模倣体類
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
ATE454383T1 (de) * 2002-06-19 2010-01-15 Biovitrum Ab Publ Neue verbindungen, deren verwendung und herstellung
US7226925B2 (en) 2002-06-19 2007-06-05 Biovitrum Ab Compounds, their use and preparation
CN102558155A (zh) 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
PT1603893E (pt) * 2003-01-29 2008-08-21 Asterand Uk Ltd Antagonistas dos receptores ep4
RS53118B (sr) * 2003-02-26 2014-06-30 Sugen Inc. Aminoheteroaril jedinjenja kao inhibitori protein kinaze
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
US20080146583A1 (en) * 2003-05-15 2008-06-19 Pfizer Inc Treatment of Incontinence
US20040235856A1 (en) * 2003-04-25 2004-11-25 Pfizer Inc Treatment of incontinence
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US8367657B2 (en) 2003-06-17 2013-02-05 Arena Pharmaceuticals, Inc. Processes for preparing 3-benzazepines
BRPI0411470A (pt) 2003-06-17 2006-07-11 Arena Pharm Inc derivados de benzazepina úteis para o tratamento de doenças associadas com o receptor de 5ht2c
EA200600071A1 (ru) * 2003-06-20 2006-08-25 Арена Фармасьютикалз, Инк. Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
AU2004257267B2 (en) 2003-07-14 2009-12-03 Arena Pharmaceuticals,Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
AU2004278382B2 (en) * 2003-09-30 2008-09-18 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2005053688A1 (en) 2003-11-26 2005-06-16 Alcon, Inc. Substituted furo[2,3-g] indazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
US20080194574A1 (en) * 2003-12-16 2008-08-14 Axxima Pharmaceuticals Ag Pyrazine Derivatives As Effective Compounds Against Infectious Diseases
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
PT1756084E (pt) * 2004-06-04 2009-02-17 Arena Pharm Inc Composto seleccionado de compostos de fórmula (i) e seus sais, solvatos, hidratos e n-óxidos farmaceuticamente aceitáveis
US8685924B2 (en) 2004-08-25 2014-04-01 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
US8114502B2 (en) * 2004-09-02 2012-02-14 3M Innovative Properties Company Substrates with multiple images
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
BRPI0518241A (pt) * 2004-11-01 2008-04-22 Amylin Pharmaceuticals Inc métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade
AU2005305036B2 (en) * 2004-11-01 2011-03-10 Amylin Pharmaceuticals, Llc Treatment of obesity and related disorders
AR051946A1 (es) * 2004-11-05 2007-02-21 Wyeth Corp Formulaciones de derivados de [1,4] diazepina [6,7,1-ij] quinolina
CA2587427A1 (en) 2004-11-17 2006-05-26 Miikana Therapeutics, Inc. Kinase inhibitors
TW200633721A (en) * 2004-12-14 2006-10-01 Shionogi & Co A pharmaceutical composition for treating constipation
ME01090B (me) 2004-12-21 2012-12-20 Arena Pharm Inc Kristalni oblici (r)-8-hloro-metil-2,3,4,5-tetrahidr0-1h-3-benzazepin hlorhidrat
PT1833473E (pt) * 2004-12-23 2009-12-17 Arena Pharm Inc Composições de modulador de receptor 5ht2c e métodos de utilização
MX2007008279A (es) * 2005-01-25 2008-02-15 Epix Delaware Inc Compuestos de arilamina sustituidos y su uso como moduladores de la 5-ht6.
AU2006228378A1 (en) * 2005-03-31 2006-10-05 Pfizer Products Inc. Cyclopentapyridine and tetrahydroquinoline derivatives
US7594976B2 (en) * 2005-05-13 2009-09-29 3M Innovative Properties Company Methods of manufacturing substrates
CA2616366A1 (en) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
NZ567241A (en) * 2005-09-30 2010-08-27 Miikana Therapeutics Inc Substituted pyrazole compounds
RU2384331C2 (ru) * 2005-12-05 2010-03-20 Пфайзер Продактс Инк. Способ лечения аномального роста клеток
SI1963302T1 (sl) * 2005-12-05 2013-04-30 Pfizer Products Inc. Polimorfne oblike inhibitorja c-met/hgfr
WO2007075555A2 (en) * 2005-12-21 2007-07-05 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
EP2518053A1 (en) 2006-04-03 2012-10-31 Arena Pharmaceuticals, Inc. Process for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine
JP5528699B2 (ja) 2006-05-16 2014-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
WO2007137955A1 (en) * 2006-05-30 2007-12-06 F. Hoffmann-La Roche Ag Piperidinyl pyrimidine derivatives
KR20090029299A (ko) * 2006-07-14 2009-03-20 화이자 프로덕츠 인코포레이티드 (7ｓ)-7-[(5-플루오로-2-메틸-벤질)옥시]-2-[(2ｒ)-2-메틸피페라진-1-일]-6,7-다이하이드로-5ｈ-사이클로펜타[ｂ]피리딘의 타르트레이트 염
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
JP2010509392A (ja) 2006-11-13 2010-03-25 ファイザー・プロダクツ・インク ジアリール、ジピリジニルおよびアリール−ピリジニル誘導体ならびにその使用
US8461161B2 (en) 2006-11-15 2013-06-11 Ym Biosciences Australia Pty Ltd Substituted pyrazines as inhibitors of kinase activity
WO2008070111A2 (en) 2006-12-05 2008-06-12 Arena Pharmaceuticals, Inc. Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates thereof
TR201802359T4 (tr) 2007-01-16 2018-03-21 Ipintl Llc Metabolik sendromun tedavi edilmesine yönelik yeni bileşim.
US20080220104A1 (en) * 2007-03-08 2008-09-11 Cappello John V Compositions for producing satiety
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20090029992A1 (en) * 2007-06-11 2009-01-29 Agoston Gregory E Substituted pyrazole compounds
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
US8822727B2 (en) * 2008-03-04 2014-09-02 Arena Pharmaceuticals, Inc. Processes for the preparation of intermediates related to the 5-HT2C agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
MX2010013726A (es) * 2008-06-12 2011-01-14 Janssen Pharmaceutica Nv Moduladores de diamino-piridina, pirimidina, y piridazina del receptor h4 de histamina.
EP2303275A4 (en) * 2008-06-17 2012-05-09 Univ Duke STANDARD RECEPTOR MODULATORS
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
AU2009309037A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8759539B2 (en) 2008-11-17 2014-06-24 Merck Sharp & Dohme Corp. Substituted bicyclic amines for the treatment of diabetes
CN102648170A (zh) 2009-06-18 2012-08-22 艾尼纳制药公司 制备5-ht2c受体激动剂的方法
AU2010264422B2 (en) * 2009-06-26 2014-12-18 Sanofi Novel fumarate salts of a histamine H3 receptor antagonist
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
US20120220567A1 (en) 2009-07-23 2012-08-30 Shipps Jr Gerald W Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
US20120253036A1 (en) 2009-12-11 2012-10-04 Yukinori Nagakura Agent for treating fibromyalgia
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US8785634B2 (en) 2010-04-26 2014-07-22 Merck Sharp & Dohme Corp Spiropiperidine prolylcarboxypeptidase inhibitors
EP2568812B1 (en) 2010-05-11 2016-10-26 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
KR20130112848A (ko) 2010-06-02 2013-10-14 아레나 파마슈티칼스, 인크. 5-ｈｔ2ｃ 수용체 아고니스트의 제조 방법
US9006268B2 (en) 2010-06-11 2015-04-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
ES2769386T3 (es) * 2010-06-23 2020-06-25 Johnson Matthey Plc Complejos de pi-alillpaladio y pi-alilníquel para uso como catalizadores en reacciones de acoplamiento carbono-carbono y carbono-nitrógeno
CA2808912C (en) 2010-09-01 2019-09-17 Zezhi Jesse Shao Modified-release dosage forms of 5-ht2c agonists useful for weight management
KR20130138770A (ko) 2010-09-01 2013-12-19 아레나 파마슈티칼스, 인크. 광학적으로 활성 산을 갖는 로르카세린의 염
WO2012030957A2 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Non-hygroscopic salts of 5-ht2c agonists
JP2013540719A (ja) 2010-09-01 2013-11-07 アリーナ ファーマシューティカルズ， インコーポレイテッド 腎欠陥を有する個体へのロルカセリンの投与
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EA201390421A1 (ru) 2010-09-22 2013-09-30 Арена Фармасьютикалз, Инк. Модуляторы рецептора gpr119 и лечение связанных с ним нарушений
US9850227B2 (en) * 2011-02-25 2017-12-26 Yuhan Corporation Diaminopyrimidine derivatives and processes for the preparation thereof
JP5728099B2 (ja) 2011-02-25 2015-06-03 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病剤として有用な新規環状アザベンゾイミダゾール誘導体
KR20150023318A (ko) * 2012-05-30 2015-03-05 에프. 호프만-라 로슈 아게 피롤리디노 헤테로사이클
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
KR20190128001A (ko) 2012-10-09 2019-11-13 에자이 알앤드디 매니지먼트 가부시키가이샤 체중 관리 방법
US9815815B2 (en) 2013-01-10 2017-11-14 Pulmokine, Inc. Non-selective kinase inhibitors
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
HK1220611A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 用於治疗胃肠道病症的组成物
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CN113388007A (zh) 2013-06-05 2021-09-14 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP3054937B1 (en) 2013-10-11 2023-07-26 Pulmokine, Inc. Spray dry formulations
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
EP4445956A3 (en) 2015-01-06 2024-12-04 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
JP2020500183A (ja) 2016-10-27 2020-01-09 プルモキネ、インコーポレイテッド 肺高血圧症の治療のための併用療法
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
JPWO2019131902A1 (ja) 2017-12-27 2020-12-10 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
CA3102136A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
CA3132731A1 (en) * 2019-03-07 2020-09-10 University Of Padova Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
CN111704582B (zh) * 2020-06-23 2021-06-11 杭州煌森生物科技有限公司 一种法匹拉韦及其衍生物的制备方法
CN115618396B (zh) * 2022-11-28 2023-04-07 云账户技术(天津)有限公司 一种数据的加密方法及装置

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL127996C (xx) * 1963-11-19
US3980781A (en) * 1966-03-31 1976-09-14 Imperial Chemical Industries Limited Fungicidal composition and method containing 2-amino-pyrimidines
GB1165283A (en) * 1967-01-17 1969-09-24 Science Union & Cie New Purine Derivatives and processes for prepararing them
US4166852A (en) 1974-08-09 1979-09-04 Produits Chimiques Ugine Kuhlmann Piperazino-pyrimidines and their use as spasmolytic agents
FR2281117A2 (fr) 1974-08-09 1976-03-05 Ugine Kuhlmann Nouvelles piperazino-pyrimidines utilisables comme medicaments
US4081542A (en) 1975-04-21 1978-03-28 Merck & Co., Inc. Piperazinylpyrazines
EG12387A (en) * 1975-04-21 1978-12-31 Merck & Co Inc Process for preparing of piperazinyl pyrazines
FR2311776A1 (fr) 1975-05-23 1976-12-17 Sogeras Diamino-2,4 bromo-5 chloro-6 pyrimidines et procede pour leur preparation
FI70411C (fi) 1980-12-29 1986-09-19 Pfizer Foerfarande foer framstaellning av nya antihypertensiva 4-amino-6,7-dimetoxi-2-piperazinokinazolin derivat
HU206337B (en) 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
DE3905364A1 (de) 1989-02-22 1990-08-23 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als tool
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
JPH0665203A (ja) 1992-06-25 1994-03-08 Elf Sanofi ピペラジンのヘテロ環誘導体
NZ254550A (en) 1992-09-28 1997-08-22 Pfizer Use of nitrogen-substituted pyrimidines to prepare medicaments useful for treatment or prevention of diabetic complications
WO1995010506A1 (en) * 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
PL313973A1 (en) 1993-10-12 1996-08-05 Du Pont Merck Pharma 1 n-alkyl-n-arylopyrimidin amines and their derivatives
US5419301A (en) * 1994-04-14 1995-05-30 Ford Motor Company Adaptive control of camless valvetrain
WO1996031488A1 (en) * 1995-04-03 1996-10-10 Sumitomo Pharmaceuticals Company, Limited Novel pyrimidine derivatives efficacious as psychotropic drug and process for the production thereof
US5795905A (en) 1995-06-06 1998-08-18 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
EP0791355B1 (en) 1996-02-29 2002-04-17 Pfizer Inc. Method of reducing tissue damage associated with ischemia
US6326368B1 (en) 1996-03-27 2001-12-04 Dupont Pharmaceuticals Company Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
KR100239800B1 (ko) * 1996-11-28 2000-03-02 손경식 4,5-디아미노 피리미딘 유도체 및 이의 제조방법
DE19710435A1 (de) 1997-03-13 1998-09-17 Hoechst Ag Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen
US6440965B1 (en) * 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
AU1738900A (en) 1998-11-19 2000-06-05 Nortran Pharmaceuticals Inc. Serotonin ligands as pro-erectile compounds
GB9902047D0 (en) 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
CN1242995C (zh) 1999-05-21 2006-02-22 比奥维特罗姆股份公司 化合物,它们的用途和制备方法
SE0002754D0 (sv) 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
EA005975B1 (ru) 2000-11-20 2005-08-25 Биовитрум Аб Соединения пиперазинилпиразинов в качестве антагонистов серотонин 5-ht2 рецептора
CA2448729A1 (en) 2000-11-20 2002-05-23 Biovitrum Ab Piperazinyl and piperidyl substituted heterocyclic compounds
SE0004245D0 (sv) * 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use

Also Published As

Publication number Publication date
IS7040A (is) 2003-11-17
IL158808A0 (en) 2004-05-12
HUP0400251A2 (hu) 2004-08-30
CZ20033431A3 (en) 2004-07-14
EA200301213A1 (ru) 2004-06-24
DOP2002000412A (es) 2002-12-30
EP1401820A1 (en) 2004-03-31
US6825198B2 (en) 2004-11-30
GEP20053655B (en) 2005-11-10
WO2003000663A1 (en) 2003-01-03
KR20040010765A (ko) 2004-01-31
GT200200120A (es) 2003-02-13
SK15712003A3 (sk) 2004-06-08
EA007183B1 (ru) 2006-08-25
SV2003001102A (es) 2003-03-18
TNSN03142A1 (fr) 2005-12-23
WO2003000666A1 (en) 2003-01-03
KR100566854B1 (ko) 2006-04-03
BG108495A (en) 2004-08-31
MXPA03011940A (es) 2004-03-26
NO20035698L (no) 2004-02-17
OA12621A (en) 2006-06-12
US20050054656A1 (en) 2005-03-10
PL367746A1 (en) 2005-03-07
PA8548901A1 (es) 2003-02-14
MA27036A1 (fr) 2004-12-20
NO20035698D0 (no) 2003-12-19
BG108491A (en) 2005-01-31
HUP0400249A3 (en) 2009-01-28
BR0210503A (pt) 2004-05-18
US20030125334A1 (en) 2003-07-03
US6995159B2 (en) 2006-02-07
AU2002309173B2 (en) 2007-04-26
BR0210471A (pt) 2004-08-10
EE200400025A (et) 2004-06-15
HUP0400249A2 (hu) 2004-08-30
OA12629A (en) 2006-06-14
JP2005501821A (ja) 2005-01-20
EA200301215A1 (ru) 2004-04-29
PL367777A1 (en) 2005-03-07
UY27343A1 (es) 2003-02-28
US20050032809A1 (en) 2005-02-10
HRP20031042A2 (en) 2005-10-31
US20050090503A1 (en) 2005-04-28
IS7041A (is) 2003-11-17
CR7168A (es) 2004-02-23
MXPA03011941A (es) 2004-03-26
MA27035A1 (fr) 2004-12-20
KR20040010767A (ko) 2004-01-31
NZ529542A (en) 2005-05-27
TNSN03143A1 (fr) 2005-12-23
CA2450491A1 (en) 2003-01-03
ZA200308843B (en) 2004-11-23
CN1630645A (zh) 2005-06-22
IL158807A0 (en) 2004-05-12
CN1745074A (zh) 2006-03-08
NO20035697D0 (no) 2003-12-19
AR036095A1 (es) 2004-08-11
ECSP034884A (es) 2004-01-28
US6894050B2 (en) 2005-05-17
EP1401819A1 (en) 2004-03-31
HUP0400251A3 (en) 2006-02-28
PE20030268A1 (es) 2003-03-19
UA74443C2 (uk) 2005-12-15
ZA200308842B (en) 2004-11-23
AP2002002561A0 (en) 2002-06-30
SK15672003A3 (sk) 2004-05-04
US20050020604A1 (en) 2005-01-27
CA2455292A1 (en) 2003-01-03
US20030105106A1 (en) 2003-06-05
JP2004534823A (ja) 2004-11-18
YU95303A (sh) 2006-08-17
CZ20033508A3 (en) 2004-05-12
ECSP034881A (es) 2004-01-28

Similar Documents

Publication Publication Date Title
EE200400026A (et) 5-HT retseptori ligandid ja nende kasutamine
IS8054A (is) Kannabinóíð viðtaka bindlar og notkun þeirra
IS8137A (is) Kannabinóíð viðtaka bindlar og notkun þeirra
DK1417175T3 (da) Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
DK1446379T3 (da) Arylanilin-beta2-adrenergiske receptoragonister
EE05002B1 (et) Indoliin-2-ooni derivaadid, nende valmistamine jakasutamine okstotsiiniretseptorite ligandidena
NO20034159D0 (no) Östrogen-gestagen-kombinasjonspreparat og anvendelse derav
NO20035121D0 (no) Ny anvendelse
EE200300339A (et) Helicobacter pylory uudsed retseptorid ja nende kasutamine
NO20033919L (no) Ny anvendelse
FI20012016L (fi) Eettereitä hajottavia bakteereita ja niiden käyttö
ATE354561T1 (de) Substituierte 1-aryl-but-3-enylamin- und 1-aryl- but-2-enylaminverbindungen
DE50214478D1 (de) Aufhänger
SE0100590D0 (sv) New composition and use
SE0103767D0 (sv) New use
SE0100062D0 (sv) New use
SE0103291D0 (sv) New use
SE0102574D0 (sv) New Use
SE0103540D0 (sv) New Use
SE0100798D0 (sv) New use
SE0103768D0 (sv) New use
SE0104092D0 (sv) New use
SE0101160D0 (sv) New use
SE0104404D0 (sv) New methods and use
ES1049528Y (es) Almohada hidroneumatica